Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-01-04
2011-01-04
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S184100, C530S350000, C435S069100, C435S069500, C435S069700, C536S023500, C536S023700
Reexamination Certificate
active
07862827
ABSTRACT:
Compositions comprising a first biological molecule from aNeisseriabacterium and a second biological molecule from aNeisseriabacterium. The term “biological molecule” includes proteins and nucleic acids. PreferredNeisseriaspecies areN. meningitidisandN. gonorrhoeae.
REFERENCES:
patent: 4239749 (1980-12-01), Buchanan
patent: 5547670 (1996-08-01), Goldstein et al.
patent: 6013267 (2000-01-01), Blake et al.
patent: 6028049 (2000-02-01), Jacobs et al.
patent: 6197312 (2001-03-01), Peak et al.
patent: 6248329 (2001-06-01), Chandrashekar et al.
patent: 6709660 (2004-03-01), Scarlato et al.
patent: 6914131 (2005-07-01), Scarlato et al.
patent: 7368261 (2008-05-01), Rappuoli et al.
patent: 7504111 (2009-03-01), Fontana et al.
patent: 7576176 (2009-08-01), Fraser et al.
patent: 7604810 (2009-10-01), Rappuoli et al.
patent: 7612192 (2009-11-01), Fraser et al.
patent: 2002/0160016 (2002-10-01), Peak et al.
patent: 2004/0092711 (2004-05-01), Arico et al.
patent: 2004/0110670 (2004-06-01), Arico et al.
patent: 2004/0167068 (2004-08-01), Zlotnick et al.
patent: 2005/0222385 (2005-10-01), Pizza
patent: 2006/0051840 (2006-03-01), Arico et al.
patent: 2006/0171957 (2006-08-01), Pizza
patent: 2007/0026021 (2007-02-01), Fraser et al.
patent: 2007/0082014 (2007-04-01), Costantino
patent: 2008/0241180 (2008-10-01), Contorni
patent: 2009/0232820 (2009-09-01), Fraser et al.
patent: 2009/0285845 (2009-11-01), Masignani et al.
patent: 0273116 (1988-07-01), None
patent: 0467714 (1992-01-01), None
patent: 1790660 (2007-05-01), None
patent: 2720408 (1995-12-01), None
patent: 2003525050 (2003-08-01), None
patent: 8901612 (1990-07-01), None
patent: 8901612 (1990-07-01), None
patent: WO-9216643 (1992-10-01), None
patent: WO 95/03413 (1995-02-01), None
patent: WO 95/03413 (1995-02-01), None
patent: WO-9533049 (1995-12-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO 97/10844 (1997-03-01), None
patent: WO 97/10844 (1997-03-01), None
patent: WO-9713860 (1997-04-01), None
patent: WO 97/28273 (1997-08-01), None
patent: WO 97/28273 (1997-08-01), None
patent: WO-9817805 (1998-04-01), None
patent: WO 99/24578 (1999-05-01), None
patent: WO 99/24578 (1999-05-01), None
patent: WO 99/36544 (1999-07-01), None
patent: WO 99/36544 (1999-07-01), None
patent: WO 99/57280 (1999-11-01), None
patent: WO 99/57380 (1999-11-01), None
patent: WO-9957280 (1999-11-01), None
patent: WO-0022430 (2000-04-01), None
patent: WO-0050075 (2000-08-01), None
patent: WO 00/66791 (2000-11-01), None
patent: WO-0071574 (2000-11-01), None
patent: WO-0071725 (2000-11-01), None
patent: WO-0131019 (2001-05-01), None
patent: WO-0152885 (2001-07-01), None
patent: WO-0164920 (2001-09-01), None
patent: WO-0164922 (2001-09-01), None
patent: WO-03010194 (2003-02-01), None
patent: WO-03020756 (2003-03-01), None
patent: WO-2004032958 (2004-04-01), None
patent: WO-2004048404 (2004-06-01), None
patent: WO-2004067030 (2004-08-01), None
patent: WO-2004112832 (2004-12-01), None
patent: WO-2005032583 (2005-04-01), None
patent: WO-2005033148 (2005-04-01), None
patent: WO-2005102384 (2005-11-01), None
patent: WO-2005106009 (2005-11-01), None
patent: WO-2006024954 (2006-03-01), None
patent: WO-2008001244 (2008-01-01), None
Houghten et al. (Vaccines, 1986, Edited by Fred Brown: Cold Spring Harbor Laboratory).
Holmes, Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Greenspan et al (Nature Biotechnology, 1999, 7:936-937).
Christodoulides et al., “Immunization with a multiple antigen peptide containing defined B- and T-cell epitopes: production of bactericidal antibodies against group BNeisseria meningitides,” Microbiology140:2951:2960, 1994.
Van Der Ley et al., “Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein,”Infection and Immunity60(8) :3156-3161, 1992.
Van Der Ley et al., “Construction ofNeisseria meningitidesstrains carrying multiple chromosomal the porA gene for use in the production of a multivalent outer membrane vesicles vaccine,” Vaccine 13(4) :401-407, 1995.
Tettelin et al., “Complete Genome Sequence ofNeisseria meningitidisSerogroup B Strain MC58,”Science, 287:1809-1815, 2000.
Abad et al. (2008). “PorB2/3 Protein Hybrid inNeisseria meningitidis,” Emerging Infectious Diseases, 14(4):688-689.
Ala'Aldeen et al. (1996). “The Meningococcal Transferrin-binding Proteins 1 and 2 are Both Surface Exposed and Generate Bactericidal Antibodies Capable of Killing Homologous and Heterologous Strains,” Vaccine 14(1):49-53.
Bartsevich et al. (Mar. 7, 1997). “Molecular Identification of a Novel Protein That Regulates Biogenesis of Photosystem I, a Membrane Protein Complex,” The Journal of Biological Chemistry 272(10):6382-6387.
Bethell et al. (2002). “Meningococcal vaccines,” Expert Review of Vaccines 1(1):75-84.
Blythe et al. (2005). “Benchmarking B cell epitope prediction: underperformance of existing methods,” Protein Sci. 14:246-248.
Boslego et al. (1991). “Gonorrhea Vaccines” Chapter 17 in Vaccines and Immunotherapy, S. Cryz (Ed.). pp. 211-223.
Bowie, J. et al. (1990). “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247: 1306-1310.
Bygraves et al. (1992). “Analysis of the Clonal Relationships Between Strains of Neisseria Meningitidis by Pulsed Field Gel Electrophoresis,” Journal of General Microbiology 138:523-531.
Caugant et al. (1987). “Genetic Structure ofNeisseria meningitidisPopulations in Relation to Serogroup, Serotype, and Outer Membrane Protein Pattern,” Journal of Bacteriology 169(6):2781-2792.
Cooney et al. (1993). “Three Contiguous Lipoprotein Genes inPasteurella haemolyticaA1 which are Homologous to a Lipoprotein Gene inHaemophilus influenzaType B,” Infection and Immunity 61(11):4682-4688.
Cruse et al. Illustrated Dict. of Immunology, 2nd ed., CRC Press, 2003. pp. 46, 166, and 382.
Dempsey et al. (1991). “Physical Map of the Chromosome ofNeisseria gonorrhoeaeFA1090 with Locations of Genetic Markers, including Opa and Pil Genes,” Journal of Bacteriology 173(17):5476-5486.
Devries et al. (Aug. 1996). “Invasion of Primary Nasopharyngeal Epithelial Cells byNeisseria meningitidisis Controlled by Phase Variation of Multiple Surface Antigens,” Infection and Immunity 64(8):2998-3006.
Ellis (1988). “New Technologies for Making Vaccines” in Vaccines. Plotkin et al. (Eds.) pp. 568-575.
Feng et al. (1996). “P55, an Immunogenic but Nonprotective 55-KilodaltonBorrelia burgdorferiProtein in Murine Lyme Disease,” Infection and Immunity. 64(1):363-365.
Gervais et al. (1992). “Putative Lipoprotein Yaec Precursor,” Database Swissport Acc No. p28635.
Greenspan et al. (1999). “Defining Epitopes: Its Not as Easy as It Seems,” Nature Biotechnology 7:936-937.
Grifantini, R. et al. (2002). “Previously Unrecognized Vaccine Candidates against Group BMeningococcusIdentified by DNA Microarrays,” Nature Biotechnology 20(9): 914-921.
Guillen et al. (1996). “Expression inEscherichia coliand Immunological Characterization of a Hybrid Class I-P64K Protein fromNeisseria meningitidis,” Biotecnologia Aplicada13(4):271-275.
Herbert et al. (1995). The Dictionary of Immunology. Academic Press: London 4thedition, 3 pages.
Herbert et al. (Eds.) (1985). The Dictionary of Immunology. Academic Press: London 3rd edition, pp. 58-59.
Holmes, E. (2001). “PSMA Specific Antibodies and their Diagnostic and Therapeutic Use,” Expert Opinion on Investigational Drugs 10(3): 511-519.
Jacobsson et al. (2009). Vaccine. 27:1579-1584.
Jolley et al. (2007). “Molecular typing of meningococci: recommendations for target choice and nomenclature,” FEMS Microbiol. Rev. 31:89-96.
Legrain et al. (1995). “Production of Lipidated Meningococcal Transferrin Binding Protein 2 inEscherichia coli,” Protein Expression and Purif
Giuliani Marzia Monica
Pizza Mariagrazia
Rappuoli Rino
Baskar Padma V
Hessler Amy
Littlefield Otis
Mondesi Robert B
Novartis Vaccines and Diagnostics SRL
LandOfFree
Combination neisserial compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination neisserial compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination neisserial compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690933